Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy

Eyer-Silva, Walter de Araújo; Couto-Fernandez, José Carlos; Caetano, Marcelo Ribeiro; Chequer-Fernandez, Saada L.; Pinto, Jorge Francisco da Cunha; Morais-de-Sá, Carlos Alberto; Morgado, Mariza G.

doi:10.1097/00002030-200211220-00031

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical remission in other conditions such as malignancies (26), infections (27) and rheumatoid arthritis is defined as a time point when the disease is very well controlled (9,28). Conversely, there was consensus among pediatric rheumatologists that CR in cSLE constitutes a time period.…”

Section: Discussionmentioning

confidence: 99%

Inactive disease and remission in childhood‐onset systemic lupus erythematosus

Mina¹,

Klein‐Gitelman²,

Ravelli³

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

Objective To define inactive disease (ID) and clinical remission (CR), and delineate variables that can be used to measure ID/CR in childhood-onset systemic lupus erythematosus (cSLE). Methods Delphi questionnaires were sent to an international group of pediatric rheumatologists. Respondents provided information about variables to be used in future algorithms to measure ID/CR. The usefulness of these variables was assessed in 35 children in ID and 31 children with minimally active lupus (MAL). Results While ID reflects cSLE status at a specific point in time, CR requires the presence of ID for ≥ 6 months and considers treatment. There was consensus that patients in ID/CR can have ≤ 2 mild non-limiting symptoms (i.e. fatigue, arthralgia, headaches or myalgia) but not Raynaud’s phenomenon, chest pain, or objective physical signs of cSLE; ANA positivity and ESR elevation can be present. CBC, renal function testing, and complement C3 all must be within the normal range. Based on consensus, only damage-related laboratory or clinical findings of cSLE are permissible with ID. The above parameters were suitable to differentiate children with ID/CR from those with MAL (area under the receiver operating characteristic curve > 0.85). Disease activity scores with or without the physician global assessment of disease activity and patient symptoms were well suited to differentiate children with ID from those with MAL. Conclusions Consensus has been reached on common definitions of ID/CR with cSLE and relevant patient characteristics with ID/CR. Further studies must assess the usefulness of the data-driven candidate criteria for ID in cSLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Inactive disease and remission in childhood‐onset systemic lupus erythematosus

Mina¹,

Klein‐Gitelman²,

Ravelli³

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…While the initiation of HAART generally improves some central nervous system (CNS) disease, its impact on the specific neurological complications of HIVM remains controversial and may not prevent progression of the disease. 5 , 6 , 9 , 12 – 14 , 17 Reports of improvement in myelopathy are few in number, and some cases have reported improvement of spasticity. Highlights from the 2013 Conference on Retroviruses and Opportunistic Infections (CROI) reference several studies that demonstrate that active disease may progressively damage the CNS despite treatment.…”

Section: Discussionmentioning

confidence: 99%

HIV-associated vacuolar myelopathy: A rare initial presentation of HIV

Rezaie

Parmar

Rendon

et al. 2020

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

HIV-associated vacuolar myelopathy, or AIDS-associated myelopathy, is a rare initial presentation of HIV. One of the common HIV-associated neurocognitive disorders, HIV-associated vacuolar myelopathy presents with advanced immunosuppression in patients and is frequently associated with dementia. However, most cases are subclinical with characteristic findings identified through physical examination and/or imaging modalities. HIV-associated vacuolar myelopathy is characterized by progressive spastic paraparesis, gait disturbance and lower extremity sensory abnormalities including vibratory sensation. Magnetic resonance imaging findings in the spinal cord are abnormal in some patients with HIV-associated myelopathy, characteristically showing spinal cord atrophy at the level of the thoracic spine, but they may also be normal. Unfamiliarity with this as initial presentation of HIV infection may lead to failure to diagnose and intervene appropriately. We present a case of newly diagnosed HIV with myelopathy and dementia with minimal spinal cord involvement on magnetic resonance imaging.

show abstract

“…CR in other conditions such as malignancies (24), infections (25), and rheumatoid arthritis is defined as a time point when the disease is very well controlled (9, 26). Conversely, there was consensus among pediatric rheumatologists that CR in cSLE constitutes a time period.…”

Section: Discussionmentioning

confidence: 99%

LTE location technologies and delivery solutions

Cherian¹,

Rudrapatna²

2013

Bell Labs Tech. J.

View full text Add to dashboard Cite

With the rapid growth of mobile communication systems, user location is proving to be an important asset for end users, operators, application service providers, enterprises, public safety and law enforcement officials, and others. There are a vast number of applications and use cases that exploit location capabilities, each with a diverse set of needs and requirements in terms of accuracy, latency, and scalability. Long Term Evolution (LTE) technology offers multiple methods for determining and delivering location information. The method chosen must meet and be tailored to the needs of the application and use case for which it is being designed. In this paper, we will discuss location determination and delivery methods in LTE, realizable and simple network architectures necessary to support them, and offer a comparative analysis and recommendations. We will also address representative use cases, their requirements, and solutions. © 2013 Alcatel‐Lucent.

show abstract

Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy

Cited by 6 publications

References 16 publications

Inactive disease and remission in childhood‐onset systemic lupus erythematosus

Inactive disease and remission in childhood‐onset systemic lupus erythematosus

HIV-associated vacuolar myelopathy: A rare initial presentation of HIV

LTE location technologies and delivery solutions

Contact Info

Product

Resources

About